Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 7/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.41 |
| ▸ | F2 | P00734 | 4/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16799584 | 1.00 | PDE5A (0.47) | PDE5ACYP4F2CYP4A11NPC1RAB9A | |
| SCHEMBL16799704 | 0.99 | PDE5A (0.46) | PDE5ACYP4F2CYP4A11NPC1RAB9A | |
| SCHEMBL16799702 | 0.99 | PDE5A (0.46) | PDE5ACYP4F2CYP4A11NPC1RAB9A | |
| SCHEMBL16800024 | 0.99 | PDE5A (0.46) | PDE5ACYP4F2CYP4A11NPC1RAB9A | |
| SCHEMBL16800021 | 0.99 | PDE5A (0.46) | PDE5ACYP4F2CYP4A11NPC1RAB9A | |
| SCHEMBL16799935 | 0.99 | PDE5A (0.46) | PDE5ACYP4F2CYP4A11NPC1RAB9A | |
| SCHEMBL20810384 | 0.90 | CYP4F2 (0.40) | PDE5ACYP4F2CYP4A11NPC1RAB9A | |
| SCHEMBL20810602 | 0.90 | PDE5A (0.48) | PDE5ACYP4F2CYP4A11NPC1RAB9A | |
| SCHEMBL16800047 | 0.89 | GPR132 (0.46) | PDE5ACYP4F2CYP4A11ALOX5 | |
| SCHEMBL16800046 | 0.89 | GPR132 (0.46) | PDE5ACYP4F2CYP4A11ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077369-B1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2019-03-13 | — | — | EP | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9908843-B2 | Benzamide derivatives useful in the treatment of muscular disorders and pain and for controlling spasticity and tremors | CANBEX THERAPEUTICS LIMITED (GB) | 2018-03-06 | — | — | US | disclosed |
| EP-3256112-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | Canbex Therapeutics Limited (GB) | 2017-12-20 | — | — | EP | disclosed |
| US-20160304441-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | UCL BUSINESS PLC (GB) | 2016-10-20 | — | — | US | disclosed |
| EP-3077369-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERSAND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | Canbex Therapeutics Limited (GB) | 2016-10-12 | — | — | EP | disclosed |
| WO-2016128771-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
| CN-105793237-A | Benzamide derivatives for the treatment of muscular disorders and pain and for the control of spasticity and tremors | 坎贝克斯治疗有限公司 | 2016-07-20 | — | — | CN | disclosed |
| WO-2015082938-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERSAND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | CANBEX THERAPEUTICS LIMITED (GB) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | HCN4, KCNJ4, KCNQ4 | PDE5A 1773/4885CYP4F2 765/4885CYP4A11 235/4885 |
| US-20160304441-A1 | BENZAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS AND PAIN AND FOR CONTROLLING SPASTICITY AND TREMORS | MUSK, MYLK2, CBR3 | PDE5A 2504/4885CYP4F2 976/4885CYP4A11 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.